Learn about the DIAMOND clinical trials for DME

If you’re living with diabetic macular edema (DME), you probably already know that diabetes can have a serious effect on your eye health.1

Diabetes is the leading cause of new cases of blindness in the United States, with DME contributing greatly to this vision loss.2, 3 DME is a complication of diabetes that can affect the central portion in the retina where vision is the sharpest.3, 4

Since DME may lead to significant vision loss that could lead to blindness if not treated, it’s crucial to speak to your doctor and ask about treatment options that may be appropriate for you.1

We are currently seeking individuals to enroll in the DIAMOND trials, two Phase 3 clinical studies evaluating OCS-01, an investigational eye drop, for the treatment of DME.5

Together, we can help advance treatment options for DME.

Find a Site Near You

To schedule a screening visit and find out if you are eligible to participate in one of the DIAMOND trials, contact a study site near you.

Find a U.S. Clinical Trial Site

OCS-01 is an investigational product and has not been approved by the FDA. Safety and efficacy of OCS-01 for diabetic macular edema have not been established.

References

1. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetic Eye Disease. Accessed August 2, 2024. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-eye-disease. 2. American Diabetes Association. Diabetes Complications. Accessed August 2, 2024. https://diabetes.org/about-diabetes/complications. 3. Duphare C, et al. Diabetic Macular Edema. Accessed August 2, 2024. https://www.ncbi.nlm.nih.gov/books/NBK554384/. 4. American Academy of Ophthalmology. Fovea. Accessed August 6, 2024. https://www.aao.org/eye-health/anatomy/fovea. 5. Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema (DIAMOND-2). NCT06172257. Accessed August 2, 2024. https://clinicaltrials.gov/study/NCT06172257.